Evotec : partner Exscientia reports topline data from EXS-21

CLINICAL DATA BUILDS UPON BODY OF EVIDENCE SUGGESTING EXS-21546 IS A HIGHLY POTENT AND SELECTIVE A2AR INHIBITOR WITH LOW CNS EXPOSURE


EXSCIENTIA ANTICIPATES... | June 14, 2022

Related Keywords

, Evotec Se Stock Exchange , News , Information , Press Release , Linical , Data , Builds , Pon , Body , F , Evidence , Asuggesting , Us , Ighly , Kpotent , End , Elective , A2ar , Inhibitor , Ith , Dow , Ns , Xscientia Evt De0005664809 ,